CY1120035T1 - Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης - Google Patents
Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασηςInfo
- Publication number
- CY1120035T1 CY1120035T1 CY20181100041T CY181100041T CY1120035T1 CY 1120035 T1 CY1120035 T1 CY 1120035T1 CY 20181100041 T CY20181100041 T CY 20181100041T CY 181100041 T CY181100041 T CY 181100041T CY 1120035 T1 CY1120035 T1 CY 1120035T1
- Authority
- CY
- Cyprus
- Prior art keywords
- wee
- kinase
- pyrimidopyrimidinones
- suspensions
- usable
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- RLJCWYYOGHGGBV-UHFFFAOYSA-N 1h-pyrimido[5,4-d]pyrimidin-2-one Chemical class C1=NC=C2NC(=O)N=CC2=N1 RLJCWYYOGHGGBV-UHFFFAOYSA-N 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
| PCT/GB2014/053793 WO2015092431A1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120035T1 true CY1120035T1 (el) | 2018-12-12 |
Family
ID=50071157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100041T CY1120035T1 (el) | 2013-12-19 | 2018-01-15 | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9850247B2 (enExample) |
| EP (1) | EP3083625B1 (enExample) |
| JP (1) | JP6437559B2 (enExample) |
| KR (1) | KR102405462B1 (enExample) |
| CN (1) | CN105829315B (enExample) |
| AU (1) | AU2014369457B2 (enExample) |
| BR (1) | BR112016014151B1 (enExample) |
| CA (1) | CA2933755C (enExample) |
| CY (1) | CY1120035T1 (enExample) |
| DK (1) | DK3083625T3 (enExample) |
| ES (1) | ES2650013T3 (enExample) |
| GB (1) | GB201322602D0 (enExample) |
| HR (1) | HRP20180080T1 (enExample) |
| HU (1) | HUE037908T2 (enExample) |
| IL (1) | IL245672B (enExample) |
| LT (1) | LT3083625T (enExample) |
| MX (1) | MX371108B (enExample) |
| NO (1) | NO3083625T3 (enExample) |
| NZ (1) | NZ720178A (enExample) |
| PL (1) | PL3083625T3 (enExample) |
| PT (1) | PT3083625T (enExample) |
| RS (1) | RS56731B1 (enExample) |
| RU (1) | RU2691105C1 (enExample) |
| SG (1) | SG11201603814TA (enExample) |
| SI (1) | SI3083625T1 (enExample) |
| SM (1) | SMT201800020T1 (enExample) |
| WO (1) | WO2015092431A1 (enExample) |
| ZA (1) | ZA201603337B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168992A1 (en) * | 2015-04-21 | 2016-10-27 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Preparation and use of novel protein kinase inhibitors |
| AU2016344040B2 (en) | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| ES2968252T3 (es) * | 2016-11-16 | 2024-05-08 | Impact Therapeutics Shanghai Inc | Compuesto 8,9-dihidroimidazol[1,2-a]pirimido[5,4-e]pirimidin-5(6H)-cetona |
| JP7076741B2 (ja) | 2016-12-27 | 2022-05-30 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| US10954253B2 (en) | 2017-01-23 | 2021-03-23 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor |
| GB201703881D0 (en) | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2018243667A1 (en) | 2017-03-31 | 2019-10-17 | Seagen Inc. | Combinations of Chk1- and Wee1 - inhibitors |
| US11345710B2 (en) | 2017-07-10 | 2022-05-31 | Impact Therapeutics (Shanghai), Inc | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof |
| WO2019037678A1 (zh) * | 2017-08-24 | 2019-02-28 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| EP3694509A4 (en) | 2017-10-09 | 2021-07-14 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| AU2018361010B2 (en) | 2017-11-01 | 2023-01-12 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Macrocyclic compound serving as Wee1 inhibitor and applications thereof |
| AU2019227823B2 (en) * | 2018-02-28 | 2024-12-12 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| EA202190885A1 (ru) * | 2018-09-27 | 2021-06-25 | Бетта Фармасьютикалз Ко., Лтд | Ингибитор fgfr4 и его применение |
| EP3875460A4 (en) | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
| CA3124569A1 (en) | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| JP2022528047A (ja) | 2019-03-22 | 2022-06-08 | ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド | Ｗｅｅ１阻害剤、その製造および用途 |
| JP2022526831A (ja) | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| EP3952879A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| HUE068061T2 (hu) | 2019-04-30 | 2024-12-28 | Wuxi Biocity Biopharmaceutics Co Ltd | WEE1 inhibitor vegyület kristályos formája és felhasználása |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CA3180664A1 (en) | 2020-06-17 | 2021-12-23 | Yuli Xie | Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor |
| US20230416247A1 (en) * | 2020-10-01 | 2023-12-28 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of microrna-21 |
| US12551584B1 (en) | 2020-12-07 | 2026-02-17 | Actinium Pharmaceuticals, Inc. | Lewis Y radioimmunotherapy for the treatment of cancer |
| JP2024502231A (ja) * | 2020-12-18 | 2024-01-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎａｖ１．８電位依存性ナトリウムチャネルを阻害するためおよびＮａｖ１．８介在疾患を治療するために有用な化学化合物 |
| TW202239409A (zh) * | 2020-12-18 | 2022-10-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| EP4332104A4 (en) | 2021-04-30 | 2025-04-16 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof |
| AU2022297176A1 (en) | 2021-06-25 | 2024-01-04 | Korea Research Institute Of Chemical Technology | Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof |
| CN116462687B (zh) | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| CN116836184B (zh) * | 2022-03-25 | 2025-07-25 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| CN117402162A (zh) | 2022-07-13 | 2024-01-16 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| RU2006136082A (ru) | 2004-03-15 | 2008-04-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Новые производныедихлорфенилпиридо[2,3]пиримидина, их получение и применение в качестве фармацевтических агентов |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| EP2155752B1 (en) | 2007-04-25 | 2018-09-19 | Merck Sharp & Dohme Corp. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
| CN101784551A (zh) | 2007-06-15 | 2010-07-21 | 万有制药株式会社 | 二环苯胺衍生物 |
| JPWO2009054332A1 (ja) * | 2007-10-23 | 2011-03-03 | 萬有製薬株式会社 | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| WO2010067886A1 (en) | 2008-12-12 | 2010-06-17 | Banyu Pharmaceutical Co.,Ltd. | Dihydropyrimidopyrimidine derivative |
| WO2010067888A1 (en) | 2008-12-12 | 2010-06-17 | Banyu Pharmaceutical Co.,Ltd. | Dihydropyrimidopyrimidine derivatives |
| JP5886310B2 (ja) * | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
| WO2012085167A1 (en) | 2010-12-22 | 2012-06-28 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| TWI532742B (zh) * | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| JP2014520855A (ja) | 2011-07-15 | 2014-08-25 | アッヴィ・インコーポレイテッド | 増殖性疾患の治療に有用な三環式キナーゼ阻害薬 |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| CN104011049A (zh) | 2011-10-20 | 2014-08-27 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
| EP2817308B1 (en) * | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
-
2013
- 2013-12-19 GB GBGB1322602.2A patent/GB201322602D0/en not_active Ceased
-
2014
- 2014-12-19 CA CA2933755A patent/CA2933755C/en active Active
- 2014-12-19 DK DK14815843.9T patent/DK3083625T3/en active
- 2014-12-19 PL PL14815843T patent/PL3083625T3/pl unknown
- 2014-12-19 US US15/105,869 patent/US9850247B2/en active Active
- 2014-12-19 CN CN201480069437.9A patent/CN105829315B/zh active Active
- 2014-12-19 ES ES14815843.9T patent/ES2650013T3/es active Active
- 2014-12-19 HU HUE14815843A patent/HUE037908T2/hu unknown
- 2014-12-19 EP EP14815843.9A patent/EP3083625B1/en active Active
- 2014-12-19 AU AU2014369457A patent/AU2014369457B2/en active Active
- 2014-12-19 KR KR1020167019551A patent/KR102405462B1/ko active Active
- 2014-12-19 SM SM20180020T patent/SMT201800020T1/it unknown
- 2014-12-19 WO PCT/GB2014/053793 patent/WO2015092431A1/en not_active Ceased
- 2014-12-19 BR BR112016014151-2A patent/BR112016014151B1/pt active IP Right Grant
- 2014-12-19 MX MX2016007801A patent/MX371108B/es active IP Right Grant
- 2014-12-19 JP JP2016541294A patent/JP6437559B2/ja active Active
- 2014-12-19 SI SI201430580T patent/SI3083625T1/en unknown
- 2014-12-19 RS RS20171338A patent/RS56731B1/sr unknown
- 2014-12-19 SG SG11201603814TA patent/SG11201603814TA/en unknown
- 2014-12-19 PT PT148158439T patent/PT3083625T/pt unknown
- 2014-12-19 HR HRP20180080TT patent/HRP20180080T1/hr unknown
- 2014-12-19 LT LTEP14815843.9T patent/LT3083625T/lt unknown
- 2014-12-19 RU RU2016123363A patent/RU2691105C1/ru active
- 2014-12-19 NO NO14815843A patent/NO3083625T3/no unknown
- 2014-12-19 NZ NZ720178A patent/NZ720178A/en unknown
-
2016
- 2016-05-17 IL IL245672A patent/IL245672B/en unknown
- 2016-05-17 ZA ZA2016/03337A patent/ZA201603337B/en unknown
-
2018
- 2018-01-15 CY CY20181100041T patent/CY1120035T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120035T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
| MX382339B (es) | Inhibidores g12c de kras. | |
| CY1124613T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
| EA201890754A1 (ru) | Соединения и способы их применения | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| MX384792B (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| EA201792348A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| EA201590997A1 (ru) | Соединения и способы их применения | |
| CY1122098T1 (el) | Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3 | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| EA201791933A1 (ru) | Ингибирование активности olig2 |